@prof19
ich kann nur mit folgender Meldung dienen. Wichtig ist m.E. der Ausblick. Wenn schlechtere Börsenzeiten auf uns zukommen, sind m.E. die Generika-Hersteller a good place to be ACTO, IPXL und TEVA sind gute Investments, wobei TEVA ein Basiswert ist.
Shares of Aceto Corp (ACET) leapt almost 11 percent after it gave an upbeat fourth-quarter and full-year outlook in the wake of forecast-beating third-quarter results. The company, which distributes chemically-derived pharmaceuticals, biopharmaceuticals and specialty chemicals, posted net income of $3.7 million, or 23 cents a share, up from 16 cents a share in the same period in 2003. The Thomson First Call average estimate was for earnings of 20 cents a share. Sales climbed to $79.6 million from $70.5 million. Looking ahead, Aceto said it is forecasting fourth-quarter earnings in the range of 20 cents to 23 cents a share, three cents ahead of the average estimate of two analysts polled by First Call. For fiscal 2004, the company is targeting earnings of 80 cents to 83 cents a share, above analyst forecasts of 78 cents.
Hier die 3 Werte auf einen Blick:
Hier ein Chartvergleich:
1 JAHR
3 JAHRE
5 JAHRE